Epidiolex, Sativex maker GW Pharmaceuticals reports Q1 revenue, loss improvement


United Kingdom-based GW Pharmaceuticals showed revenue of $39.2 million for the quarter ended March 31, 2019, compared with $3 million in the same period a year ago. The maker of cannabis-derived medications, including Sativex and Epidiolex, recorded a net loss for the quarter of $50.1 million compared with a year-ago net loss of $69.5 million. […] Epidiolex, Sativex maker GW Pharmaceuticals reports Q1 revenue, loss improvement is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs
Source: MjBizDaily.com
Epidiolex, Sativex maker GW Pharmaceuticals reports Q1 revenue, loss improvement